Cryoport, Inc. (CYRX) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Cryoport, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Cryoport is a global leader in integrated temperature-controlled supply chain solutions for the life sciences industry, with a primary focus on the Cell and Gene Therapy (CGT) market. The company operates through two reportable segments: Life Sciences Services (logistics, biostorage, cryopreservation) and Life Sciences Products (cryogenic systems, freezers, dewars). As of December 31, 2024, the company supported 701 clinical trials and 19 commercial cell and gene therapies.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Total Revenue | $228.4 million | $233.3 million |
| Net Loss | $(114.8) million | $(99.6) million |
| Gross Margin | 43.6% | 42.6% |
| Adjusted EBITDA | $(15.1) million | $(8.3) million |
| Cash & Cash Equivalents | $45.3 million | $46.3 million |
| Short-Term Investments | $216.5 million | $410.4 million |
| Total Debt (Convertible Notes) | $200.5 million (Principal) | $385.5 million (Principal) |
| Working Capital | $277.0 million | $489.5 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2.1% to $228.4 million. This was driven by a 16.2% decline in Life Sciences Products revenue ($74.7M vs $89.2M) due to decreased demand for cryogenic systems, partially offset by a 6.6% increase in Life Sciences Services revenue ($153.7M vs $144.1M).
- Significant Impairment Charges: The company recorded a non-cash impairment loss of $63.8 million. This included a full impairment of goodwill ($54.6 million) and trademark impairment ($9.2 million) related to the MVE Biological Solutions reporting unit.
- Debt Reduction: The company repurchased approximately $185.0 million in aggregate principal amount of its 2026 Convertible Senior Notes, resulting in an $18.5 million gain on extinguishment of debt. Total outstanding principal on convertible notes dropped significantly from ~$385.5 million in 2023 to ~$200.5 million in 2024.
- Segment Realignment: Effective Q4 2024, the company transitioned from a single reportable segment to two segments: Life Sciences Services and Life Sciences Products.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong demand for services, particularly in BioStorage/BioServices (+10.6%) and Commercial Cell & Gene Therapy (+20.1%). The company continues to invest in new capabilities, including the IntegriCell cryopreservation platform and the HV3 shipping system. Management believes current cash, short-term investments, and projected cash flows will satisfy operational requirements for at least the next 12 months.
Key Risks & Contingencies:
- Profitability: The company has a history of significant losses and an accumulated deficit of $757.2 million. There is no assurance it will achieve or sustain profitability.
- Debt Obligations: Significant indebtedness limits cash flow flexibility. The company has $200.5 million in convertible senior notes outstanding (due 2025 and 2026).
- Asset Impairment: Future goodwill or intangible asset impairments could materially impact results if operating performance projections are not met.
- Market & Operational Risks: Exposure to foreign currency fluctuations, supply chain disruptions, and the competitive landscape in the life sciences sector.
Investor Verification Checklist
- Debt Maturity Profile: Verify the repayment schedule for the remaining $200.5 million in convertible senior notes (2025 and 2026 maturities) and assess refinancing or conversion risks.
- MVE Segment Viability: Review the specific drivers behind the full goodwill impairment of the MVE Biological Solutions unit and the outlook for its future cash flows.
- Liquidity Runway: Confirm the company's ability to fund operations without additional capital raises, given the $114.8 million net loss and $16.3 million cash burn from operating activities.
- Revenue Mix Shift: Monitor the trend of declining product revenue versus growing service revenue to understand the long-term margin profile.
- Preferred Stock Terms: Review the terms of the Series C Convertible Preferred Stock (4.0% paid-in-kind dividend, liquidation preference) and its impact on common equity dilution.